English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Granupas (Para-aminosalicylic acid Lucane) (para-aminosalicylic acid) – Summary of product characteristics - J04AA01

Updated on site: 07-Oct-2017

Medication nameGranupas (Para-aminosalicylic acid Lucane)
ATC CodeJ04AA01
Substancepara-aminosalicylic acid
ManufacturerLucane Pharma

1.NAME OF THE MEDICINAL PRODUCT

GRANUPAS 4 g gastro-resistant granules

2.QUALITATIVE AND QUANTITATIVE COMPOSITION

Each sachet contains 4 g of para-aminosalicylic acid.

For the full list of excipients, see section 6.1.

3.PHARMACEUTICAL FORM

Gastro-resistant granules

The granules are small off white/ light brown coloured approximately 1.5mm diameter.

4.CLINICAL PARTICULARS

4.1Therapeutic indications

GRANUPAS is indicated for use as part of an appropriate combination regimen for multi-drug resistant tuberculosis in adults and paediatric patients from 28 days of age and older when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability (see section 4.4).

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

4.2Posology and method of administration

Posology

Adults

4 g (one sachet) three times per day.

The recommended schedule is 4 g every 8 hours. GRANUPAS can be taken with food. Maximum daily dose is 12 g. Usual duration of treatment is 24 months.

Paediatric population

The optimal dose regimen in children is uncertain. Limited pharmacokinetic data suggest no substantial difference between adults and children.

For infants, children and adolescents the dosage will be adapted to the patient’s weight at 150 mg/kg per day, divided in two intakes. A dosing spoon is provided to measure small doses below 4g for young children.

The safety and efficacy of GRANUPAS in neonates have not been established. No data are available.

Desensitization

Desensitization can be accomplished by starting with 10 mg para-aminosalicylic acid given as a single dose. The dosage is doubled every 2 days until reaching a total of 1 gram after which the dosage is divided to follow the regular schedule of administration. If a mild temperature rise or skin reaction develops, the increment is to be dropped back one level or the progression held for one cycle. Reactions are rare after a total dosage of 1.5 g.

Method of administration

Oral use.

The contents of the sachet should be added to a glass of orange or tomato juice. They will not dissolve, but swirling the juice in the glass will help re-suspend the granules if they sink. It should be drunk at once ensuring that the granules are not left in the glass. Any granules left-over at the bottom of the glass should be swallowed immediately by adding a small quantity of liquid. Smaller doses in children should be measured using the dosing spoon and given by sprinkling on apple sauce or yogurt.

The medicinal product should be swallowed immediately after mixing with orange juice, tomato juice, apple sauce and yogurt whilst the granules are intact.

The granules should not be crushed or chewed.

4.3Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Severe renal disease. Patients with severe renal impairment should not receive GRANUPAS. Patients with severe renal disease will accumulate the inactive acetyl metabolite of para-aminosalicylic acid.

4.4Special warnings and precautions for use

Mild to moderate renal impairment

Given that the metabolites of para-aminosalicylic acid are largely excreted via glomerular filtration, caution is warranted in patients with mild to moderate renal impairment (see also section 4.3).

Gastric ulcer

GRANUPAS should be used with caution in patients with peptic ulcer.

Hepatic impairment

GRANUPAS should be used with caution in patients with hepatic impairment.

Hepatic toxicity

Para-aminosalicylic acid may cause hepatitis. The first symptoms usually appear within three months of the start of therapy with a rash as the most common adverse reaction followed by fever and much less frequently by gastrointestinal disturbances of anorexia, nausea or diarrhoea. Treatment should be stopped immediately in this case.

Hypersensitivity

The patient must be monitored carefully during the first three months of therapy and treatment must be discontinued immediately at the first sign of a rash, fever or other premonitory signs of intolerance. See section 4.2 for posology adjustements for desensitization.

Hypothyroidism in HIV co-infected patients

Para-aminosalicylic acid may be associated with an increased risk of hypothyroidism in HIV co- infected patients. Thyroid function should be monitored in HIV co-infected patients before commencing treatment and regularly during treatment, in particular when para-aminosalicylic acid is co-administered with ethionamide/prothionamide.

Patients should be advised that the skeletons of the granules may be seen in the stools.

4.5Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed with GRANUPAS.

Results from literature suggest the following:

Vitamin B12

Vitamin B12 absorption may be reduced by para-aminosalicylic acid with clinically significant erythrocyte abnormalities developing after depletion; patients on therapy of more than one month should be considered for maintenance of vitamin B12.

Malabsorption syndrome

A malabsorption syndrome can develop in patients on para-aminosalicylic acid, but is usually not complete. The complete syndrome includes steatorrhoea, an abnormal small bowel pattern on x-ray, villus atrophy, depressed cholesterol, reduced D-xylose and iron absorption. Triglyceride absorption is always normal.

Digoxin

Para-aminosalicylic acid may decrease the gastrointestinal absorption of digoxin, by inhibiting the absorption function of intestinal cells. Serum digoxin levels should be monitored in patients on concomitant therapy.

Ethionamide

Co-administration of para- aminosalicylic acid and ethionamide may intensify adverse reactions of para-aminosalicylic acid, mainly the gastrointestinal effects, including jaundice, hepatitis, nausea, vomiting, diarrhoea, abdominal pain or anorexia. Ethionamide should be withdrawn if these effects are significant.

Diphenylhydramine

This medicinal product decreases the gastrointestinal absorption of para-aminosalicylic acid, and should not be administered concomitantly.

Antiretrovirals

No drug interaction studies have been conducted in patients with HIV infection taking antiretroviral agents and para-aminosalicylic acid. Given the metabolic pathway of GRANUPAS no significant drug interaction is anticipated.

4.6Fertility, pregnancy and lactation

Pregnancy

There are no or limited data from the use of para-aminosalicylic acid in pregnant women. Studies in animals have shown some embryologic toxicity (see section 5.3).

Literature reports on para- aminosalicylic acid in pregnant women always report co-administration of other medicinal products. As there are no adequate and well controlled studies of para- aminosalicylic acid in humans, GRANUPAS should be given to a pregnant woman only if clearly needed.

Breastfeeding

Para-aminosalicylic acid is excreted into breast milk, therefore breastfeeding mothers should not breastfeed during treatment.

Fertility

There is no evidence available on the effect of para-aminosalicylic acid on fertility.

4.7Effects on ability to drive and use machines

Para-aminosalicylic acid has negligeable influence on the ability to drive and use machines.

4.8Undesirable effects

Summary of the safety profile

Most frequent adverse reactions were related to the gastrointestinal system. Cutaneous

hypersensitivity reactions were also frequent as well as adverse reactions related to the nervous system.

Tabulated list of adverse reactions

In the table below all adverse reactions are listed by system organ class and by frequency. Frequency is defined as very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the availabledata). Within each frequency grouping, adverse reactions are presented in order of decreasingseriousness.

System Organ Class

Frequency

Adverse reaction

Blood and lymphatic system

Very rare

Thrombocytopenia, purpura, leukopenia,

disorders

anemia, methemoglobinemia, agranulocytosis

 

Metabolism and nutrition

Rare

hypothyroidism*

disorders

Very rare

Hypoglycemia

 

Very rare

Tendon pain, headache, visual abnormalities,

Nervous system disorders

peripheral neuropathy, dizziness

 

 

Common

Giddiness, vestibular syndrome

 

Common

abdominal pain, vomiting, nausea, bloating,

 

diarrhea, soft stools,

 

 

Gastrointestinal disorders

Uncommon

anorexia,

 

Malabsorption syndrome, peptic ulcer,

 

 

 

Rare

gastrointestinal bleeding, jaundice, metallic

 

 

taste

Skin and subcutaneous tissue

Common

Cutaneous hypersensitivity, skin rash

disorders

Rare

urticaria

Renal and urinary disorders

Very rare

crystalluria

 

 

Decreased prothrombine level, hepatocytolysis.

Investigations

Very rare

Increased blood alkaline phosphatase,

 

 

transaminases. weight loss

*Description of selected adverse reactions

Hypothyroidism in HIV co-infected patients is a very common event and occur in ≥1/10 subjects, particularly when PAS is administered with ethionamide/prothionamide.

Paediatric population

Frequency, type and severity of adverse reactions in children are expected to be the same as in adults.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

4.9Overdose

No case of overdose in adults or paediatrics has been reported. Treatment is symptomatic and supportive.

5.PHARMACOLOGICAL PROPERTIES

5.1Pharmacodynamic properties

Pharmacotherapeutic group: Antimycobacterials, drugs for treatment of tuberculosis ATC code:

J04AA01

Mechanism of action

Aminosalicylic acid is bacteriostatic against Mycobacterium tuberculosis. It inhibits the onset of bacterial resistance to streptomycin and isoniazid.

The mechanism of action of para-aminosalicylic acid resembles the sulfonamides, competing with paraminobenzoic acid (PABA) for dihydropteroate synthetase (DHP), a key enzyme in the biosynthesis of folates. However, para-aminosalicylic acid appears to be a weak inhibitor of DHP in vitro, raising the possibility that it may have a different target. Para-aminosalicylic acid is acetylated in the liver and converted into the inactive metabolite, N-acetyl-para-aminosalicylic acid which is devoid of bacteriostatic activity. The plasma half-life of this agent is about 1 hour, the concentration is not substantially altered in hepatic dysfunction. The concentration of the metabolite may be increased in cases of renal failure.

5.2Pharmacokinetic properties

Absorption

GRANUPAS is a gastro-resistant preparation and, therefore, the acid-resistant coating of the granules protects against degradation in the stomach therefore preventing the formation of meta-aminophenol (a known hepatotoxin). The small granules are designed to escape the restriction on gastric emptying of large particles. Under neutral conditions as are found in the small intestine or in neutral foods, the acid-resistant coating is dissolved within one minute.

Care must be taken in the administration of these granules to protect the acid-resistant coating by maintaining the granules in an acidic food during dosage administration.

Because the granules are protected by an enteric coating, absorption does not commence until they leave the stomach. The soft skeletons of the granules remain and may be seen in the stools.

In a single dose (4 grams) pharmacokinetic study in healthy adult volunteers (N=11) the initial time to a 2 µg/mL serum level of aminosalicylic acid was 2 hours with a range of 45 minutes to 24 hours; the median time to peak was 6 hours with a range of 1.5 to 24 hours; the mean peak level was 20 µg/mL with a range of 9 to 35µg/mL: a level of 2µg/mL was maintained for an average of 8 hours with a range of 5 to 9.5 a level of 1 µg/mL was maintained for an average of 8.8 hours with a range of 6 to 11.5 hours.

Distribution

Para-aminosalicylic acid is distributed in various tissues and fluids including the lungs, kidneys, liver and peritoneal fluid. Pleural or synovial fluid concentrations are approximately equal to plasma. The drug does not cross the blood brain barrier in patients unless the meninges are inflamed, when the concentration of para-aminosalicylic acid in cerebrospinal fluid is about 10 to 50% of the plasma. It is unknown whether it passes through the placental barrier. Small amounts of this agent are distributed in the milk and bile.

Plasma protein binding is about 50 to 60%, the kinetic distribution has a half-life of 0.94 hours and a volume of distribution of 1.001 L/kg.

Biotransformation

The major metabolites of PAS are produced by conjugation to glycine in para-aminosalicyluric acid (PASU) for up to 25% of the dose and to N-acetyl in N-acetyl para-aminosalicylic acid (Ac-PAS) for up to 70% of the dose. Together they constitute more than 90% of the total metabolites of PAS found in urine.

Elimination

In a single dose study the plasma half-life of para-aminosalicylic acid administered as GRANUPAS was 1.62±0.85 h.

Para-aminosalicylic acid and its metabolites are excreted by glomerular filtration and tubular secretion.

The cumulative excretion of para-aminosalicylic after 24 hours is 84% of an oral dose of 4 g, 21% as para-aminosalicylic acid and 63% as the acetylated form. The acetylation process is not genetically determined as is the case for isoniazid.

5.3Preclinical safety data

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology and repeated dose toxicity.

The data available from a rat embrofetal development study, where animals were given sodium aminosalicylate (3.85 to 385 mg/kg) were limited. Bone defects were observed at 77 mg/kg only.and increased fetal weight was noted at the other doses. Other malformations were observed; however, the exact nature of these findings is unknown. The lack of a dose-response relationship suggests that the findings are not of clinical relevance, but it is noted that the findings were observed at doses below those proposed clinically. In the rabbit, sodium aminosalicylate had no effects on embryofetal development; however, the doses evaluated were below those proposed clinically.

Sodium aminosalicylic acid was not mutagenic in Ames test strain TA 100. In human lymphocyte cultures in-vitro clastogenic effects of achromatic, chromatid, isochromatic breaks or chromatid translocations were not seen at 153 or 600 µg /mL but at 1500 and 3000 µg /mL there was a dose related increase in chromatid aberrations. An in vivo genotoxicity study (micronucleus test) has been conducted with para-aminosalicylic acid. Results indicate that para-aminosalicylic acid was considered not to have produced any clastogenic effect in mice treated at non-toxic dose levels (examined 24 hours after 2 daily administrations of 312.5 to 1250 mg/kg).

6.PHARMACEUTICAL PARTICULARS

6.1List of excipients

Colloidal silicon dioxide

Dibutyl sebacate

Methacrylic acid – Ethyl acrylate Copolymer (1:1) Dispersion 30%

Hypromellose

Microcrystalline cellulose

Talc

6.2Incompatibilities

Not applicable.

6.3Shelf life

2 years.

6.4Special precautions for storage

Do not store above 25°C.

The sachets can be stored below 25°C up to 24 hours after first opening.

6.5Nature and contents of container

Sachets consisting of paper/low density polyethylene/aluminium foil/primer/low density polyethylene.

Pack size of 30 sachets. A calibrated measuring spoon is provided.

6.6Special precautions for disposal and other handling

The granules should not be crushed or chewed.

DO NOT USE if sachet is swollen or if the granules have lost their light brown colour, and are turning dark brown or purple.

Any unused product or waste material should be disposed in accordance with local requirements.

7.MARKETING AUTHORISATION HOLDER

Lucane Pharma, 172 rue de Charonne 75011 Paris

France

8.MARKETING AUTHORISATION NUMBER(S)

EU/1/13/896/001

9.DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 07 April 2014.

10.DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines Agency: http://www.ema.europa.eu.

Comments

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
  • Help
  • Get it on Google Play
  • About
  • Info on site by:

  • Presented by RXed.eu

  • 27558

    prescription drugs listed